Kornimate/medical-research-clean huggingface dataset:
the effect of exercise on motion perception and fear in low back pain

Conditions: Low Back Pain

Summary: nonspesific low back pain (nlbp), which negatively affects functionality, activity participation, and financial situation, is now one of the leading causes of disability in the world. in nlbp, pain causes kinesiophobia known as fear of movement and limitation of activity. contrary to what is known, this cycle aggravates pain. with this result, it is suggested that the exercise to be done will improve the perception of benefit in the person and eliminate the fear of movement, and that it will cure the disease. in this context, the aim of the study is to examine the effect of exercise on the perception of exercise and fear of movement in patients with nlbp.

the study will be composed of volunteers, non-specific low back pain individuals who meet the inclusion criteria. first of all, the demographic and clinical characteristics of the patients will be questioned with the evaluation form. the personal information of the patients (gender, height, weight, smoking, etc.) and clinical status (pain type, pain intensity, trunk flexibility measurements) will be recorded by the physiotherapist in the evaluation form. in addition to these measurements, the state of fear of physical movement and activity will be evaluated with the tampa kinesiophobia scale.

Eligibility criteria:
inclusion criteria: * voluntarily accepting the study * having nonspecific low back pain for 3 months or longer * not having had spinal surgery in the last 6 months * not having an orthopedic or neurological disability that would prevent them from doing their exercises * patients who regularly continue their exercises without interrupting exclusion criteria: * patients with non-specific low back pain who do not meet the inclusion criteria and want to drop out of the study

Keywords: nonspesific low back pain flexibility kinesiphobia pain
treatment of adult traumatic rib fractures with percutaneous cryoneurolysis

Conditions: Rib Fractures

Summary: the purpose of this research study is to examine the effectiveness of using the iovera smart time 190, for ultrasound-guided cryoneurolysis, in trauma patients 18-64 years old with rib fractures that are not candidates for surgical stabilization. this will offer patients the benefits of cryoneurolysis of the intercostal nerves, thereby providing short and long term pain control while their ribs heal. the iovera smart tip 190 is fda approved for cryoneurolysis.

the purpose of this research study is to examine the effectiveness of using the iovera smart time 190, for minimally invasive ultrasound-guided cryoneurolysis, in trauma patients 18-64 years old with rib fractures that are not candidates for surgical stabilization. this procedure will offer patients the benefits of cryoneurolysis (freezing) of the intercostal nerves, thereby providing short and long term pain control while their ribs heal. patients in the intervention arm will receive cryoneurolysis via the iovera device and patients in the control arm will receive standard of care which typically includes multimodal pain therapy and pulmonary toilet. short and long term pain relief will be compared among both arms.

Eligibility criteria:
inclusion criteria: * patients 18 to 64 years with any acute rib fracture between rib 3 and rib 9 * pain score equal to or greater than 5 with deep inspiration * presenting and admitted to stanford adult emergency department, having a trauma consult, and being admitted to the trauma floors of stanford healthcare (shc) for their inpatient stay exclusion criteria: * radiographic evidence of metastasis to ribs * glasgow coma scale (gcs) score \<13 * patients undergoing ssrf (surgical stabilization of rib fractures) * rib fractures located \< 3cm from spinous process * coagulopathy (inr \>1.5, plt \< 100) * other factors precluding cryoneurolysis at the attending's discretion * if only ribs broken are 1,2 or 10,11,12 * inability to be positioned for the procedure * if the patient has the following conditions that the manufacturer of the iovera device advises against using the device if present: cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, raynaud's disease, open and/or infected wounds at or near the treatment site.
botox and suction-curettage for treatment of excessive underarm sweating (axillary hyperhidrosis)

Conditions: Axillary Hyperhidrosis

Summary: the purpose of this study is to compare the effectiveness of two methods in the treatment of excessive underarm sweating (axillary hyperhidrosis): suction-curettage and botox injections. suction-curettage is a method in which the doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. it is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located. this method has been shown in some studies to effectively reduce underarm sweating for months at a time. botox is a food and drug administration (fda) approved drug that in small doses, paralyses muscles. it is most commonly and famously used in the treatment of facial wrinkles. however, it has also been approved to treat excessive sweating. when injected in areas that sweat excessively, sweating can be significantly reduced in that area for months at a time. this study is a pilot study designed to determine feasibility of these procedures.


Eligibility criteria:
inclusion criteria: * ages 18 to 65 * bmi 18.5 - 29.99 * diagnosis of bilateral axillary hyperhidrosis refractory to previous topical therapies * subject is in good health * subject has the willingness and ability to understand and provide informed consent exclusion criteria: * under age 18 or over age 65 * pregnancy or lactating * bmi ≥ 30 or ≤18.4 * subjects who have undergone axillary suction/curettage any time in the past * subjects who have undergone axillary bt-a injections in the past year * subjects currently taking blood thinners or who have had chemotherapy or radiation within the last 6 months * subjects with a history of a bleeding disorder * subjects with an open, non-healing sore or infection near site of procedure * subjects with allergies to iodine, starch powder, albumin, or any botulinum toxin product

Keywords: sweating sweat underarm axillary hyperhidrosis botox liposuction suction-curettage suction curettage
a dose-escalating study of ro 31-8959 ( hiv protease inhibitor ) in patients with hiv disease.

Conditions: HIV Infections

Summary: to investigate the toxicity, antiviral activity, and pharmacokinetics in hiv-infected patients receiving 16 weeks of oral saquinavir mesylate ( ro 31-8959 ) at one of two doses.

cohorts of 16 patients receive 1 of 2 doses of ro 31-8959 for 20 weeks. administration of the higher dose will proceed only after 2-week safety data for the first eight patients on the lower dose has been reviewed.

Eligibility criteria:
inclusion criteria patients must have: * documented hiv infection. * cd4 count 200 - 500 cells/mm3. * no evidence of viral resistance. * hiv rna quantifiable by pcr. * negativity for hbsag, hbeag, and anti-hbc. note: * fifty percent of patients must have measurable p24 antigen levels (\> 31 pg/ml). exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * active opportunistic infection requiring immediate treatment, such as tuberculosis, cytomegalovirus, cerebral toxoplasmosis, and pneumocystis carinii pneumonia. * unable to maintain adequate oral intake. * clinically significant vomiting and/or diarrhea. * malignancy, visceral kaposi's sarcoma, or lymphoma that will require systemic chemotherapy within the next 12 months. * unable to comply with protocol requirements, in the judgment of the investigator. * any grade 3 or worse laboratory or clinical abnormality. concurrent medication: excluded: * antineoplastic agents. * concomitant or maintenance treatment with excluded experimental drugs and drugs with known nephrotoxic or hepatotoxic potential. concurrent treatment: excluded: * radiation therapy other than local skin radiation therapy. patients with the following prior conditions are excluded: * unexplained temperature \>= 38.5 c (101.5 f) persisting for 14 days or more within a 30-day period. * unexplained, chronic diarrhea persisting for 14 days or more within a 30-day period. prior medication: excluded: * prior treatment with an hiv proteinase inhibitor. * azt within 30 days prior to study entry or lasting more than 1 year. * other antiretroviral therapy (besides azt) within 30 days prior to study entry or lasting more than 14 days. * acute therapy for an opportunistic infection within 14 days prior to study entry.

Keywords: aids-related complex saquinavir hiv protease inhibitors
the effects of neuromuscular exercise training on core stability and hip strength in healthy adolescent females

Conditions: Anterior Cruciate Ligament Injury

Summary: this study is an evaluation of the effects of a neuromuscular training program on hip strength and core stability. it is a randomized clinical trial evaluating pre and post scores.


Eligibility criteria:
inclusion criteria: * healthy adolescent females between 12 and 18 years old exclusion criteria: * lower body injuries in the last 6 months or lower body injuries that they are currently receiving treatment * inability to participate in 5 week nme training program
outcome of physiotherapy after surgery for cervical disc disease: a prospective multi-centre trial

Conditions: Radiculopathy

Summary: many patients with cervical disc disease have long-lasting and complex symptoms with chronic pain, low levels of physical and psychological function and sick-leave. surgery on a few segmental levels might be expected to solve the disc-specific pain but not the non-specific neck pain and the patients'illness. as much as 2/3 of the patients have been reported to have remaining physical/ psychological disability long-term after surgery. a structured physiotherapy programme after surgery may improve patients'function and return to work. the main purpose of the study is to evaluate what a well structured rehabilitation program adds to the customary treatment after surgery for radiculopathy due to cervical disc disease in respect to function, disability, workability and cost effectiveness. the study is a prospective randomised controlled multi-centre study, with an independent and blinded investigator comparing two alternatives of rehabilitation. 200 patients in working age, with cervical disc disease with clinical findings and symptoms of cervical nerve root compression will be included after informed consent. after inclusion in the study patients will be randomised to one out of the two alternatives of physiotherapy, (a) customary treatment (information/ advice on the specialist clinic) or (a+b) active physiotherapy; standardised and structured program of neck specific exercises combined with a behavioural approach plus customary treatment. patients will be evaluated both clinically and with questionnaires before surgery, 6 weeks, 3 months, 6 months, 12 months and 24 months after surgery. main outcome variable are neck specific disability. cost-effectiveness will be calculated. the inclusion will preliminary be closed 2012. the study could contribute to a better clinical decision making, a better health care which will reduce physical, mental and social costs for the patients, and improve the rates of patients returning to and staying at work.


Eligibility criteria:
inclusion criteria: * patients will be included from four neurosurgical clinics in the south of sweden and the rehabilitation will be performed in primary care units in several counties. * patients in working age, with mri-verified cervical disc disease with clinical findings and symptoms of cervical nerve root compression and who have had surgery with anterior decompression and fusion or posterior surgery (foraminotomy/ laminectomy) will be included after informed consent. exclusion criteria: * patients with myelopathy or with a disease or trauma contraindicated to perform the treatment program or the measurements will be excluded and so also patients with lack of familiarity of the swedish language or with known drug abuse.

Keywords: rehabilitation cervical spine radiculopathy disc surgery
effects of resveratrol in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: animal studies indicate that resveratrol, a phytoalexin enriched in the skin of red grapes and a constituent of red wine, is associated with longevity likely through the increased production of a protein, sirt1. the trial is a proof-of-concept study primarily designed to examine for the first time in humans, the effect of 12 weeks of oral resveratrol on skeletal muscle sirt1 expression in 10 patients with t2dm in a randomized, placebo-controlled, double-blind fashion. secondary outcomes include measures of ampk, p-ampk and glut4 expression levels, energy expenditure, physical activity levels, distribution of abdominal adipose tissue and skeletal muscle fiber type composition, body weight, hba1c, plasma lipid subfraction, adiponectin levels and insulin sensitivity.

eligible criteria include chinese males, aged between 40 and 69 years old, with t2dm with a hba1c of 7.1 to 12% and who have been on a stable oral hypoglycemic regimen for the past 3 months. subjects who were insulin-dependent, with renal or liver impairment or who were terminally ill were excluded.

Eligibility criteria:
inclusion criteria: 1. ability to give informed consent 2. chinese male 3. age 40 to 69 yrs old 4. for subjects with type 2 diabetes mellitus * diagnosis of type 2 diabetes mellitus based on moh criteria and, * hba1c \>6.5 during screening exclusion criteria: willing to abstain from ingesting large quantities of resveratrol-containing foods (eg. red wine, nuts) cancer diagnosis that is currently under treatment, is clinically detectable, or that has been treated within the past 5 years terminal disease or on palliative care current excessive alcohol intake (\>21 units per week for men; 14 units per week for women) on maximal doses of 3 or \> oral hypoglycaemic agents on insulin therapy or known type 1 diabetes mellitus past history of documented or suspected hypoglycemia within last 3 months past history of recurrent hypoglycemia past history of serious hypoglycemia as defined by documented hypoglycemia requiring hospital admission past history of hyperglycemic emergencies within last 6 months past or current history of hemorrhagic strokes on anti-platelet agents, non-steroidal anti-inflammatory drugs (nsaids), anti-coagulation therapy or omega-3 fatty acids history of unexplained bleeding disorders history of any grape allergy history of allergy to local anaesthetic history of surgery with surgery with clips, staples or stents presence of cardiac pacemaker or metallic foreign body in any part of the body on alternative or traditional medications treated with another investigational drug within last 6 months poorly controlled hypertension (sbp \>/= 160 or dbp \>/= 100) within last one month alt and/or ast \> 1.5 times above upper limit of normal within last 6 months gfr \< 50 ml/min/1.73m2 (mdrd equation) within last 6 months

Keywords: resveratrol sirt1 ampk
study comparing effect on carotid atherosclerosis following conversion from tacrolimus to sirolimus post-transplant in kidney transplant patients

Conditions: Atherosclerosis; Kidney Failure

Summary: the purpose of this study is to determine whether immunosuppression by tacrolimus, mycophenolate mofetil, and prednisone compared to conversion to sirolimus, mycophenolate mofetil, and prednisone affect the progression of atherosclerosis in renal transplant recipients.

a decision to terminate the study was taken in november 2011 and a communication to that effect sent to all participating sites on november 18. all sites were asked to have patients returned to the sites and have all end of study procedures performed by dec 31, 2011. the decision to terminate this study was made following the conduct of an interim analysis which demonstrated that the study did not reach its primary endpoint. the termination of this study was not driven by any safety concerns and had no impact on subject safety and well-being.

Eligibility criteria:
inclusion criteria: at least one of the following characteristics: * history of dialysis for at least 3 years. * history of diabetes for at least 5 years. * hypertension or ischemic nephropathy as a cause of the end stage renal disease or loss of the first transplant. * history of coronary artery disease, stroke, myocardial infarction, or amputation for vascular disease. exclusion criteria: * history of malignancy within the last 5 years (except adequately treated skin cancer). * recipients of non-renal organ transplant. * active gastrointestinal disease that may interfere with drug absorption. * active hiv, hepatitis b or c infection. * women who are pregnant or breastfeeding.

Keywords: kidney transplant renal transplant immunosuppression atherosclerosis graft rejection
this study explores whether adding natural elements like plants and sunlight to indoor gyms makes exercise feel easier, more enjoyable, and improves performance. by comparing workouts in nature-inspired and plain gym settings, it aims to find better ways to design fitness spaces in cities.

Conditions: Biophilic Environmental Design; Traditional Exercise Design

Summary: the goal of this observational study is to examine whether exercising in a biophilic environment - a space designed to include natural elements like real plants, simulated sunlight, nature sounds, and outdoor views - can improve exercise performance and enjoyment compared to a standard indoor gym environment in male college students age 18-25 who have regularly exercised prior. the main question it aims to answer is: "can biophilic design enhance the physical and mental benefits of indoor exercise?" researchers will compare the two environments to see if there is any changes in exercise performance and enjoyment for each participant. participants will complete a treadmill fitness test in both settings to compare physical outcomes like maximal aerobic capacity, so the maximal amount of oxygen one can use during exercise, as well as perceived effort. after each treadmill test participants will be given surveys where they will be asked to evaluate their mood and enjoyment in that environment.


Eligibility criteria:
inclusion criteria: * men between 18 and 25 years exclusion criteria: * resting bp greater than 140/90 * resting hr greater than 100 bpm * bmi greater than 30 kg/m\^2 * inability to exercise at moderate to vigorous intensities * major illness/health complication in the past

Keywords: exercise biophilia environmental design mood exercise enjoyment
a study of dryvax vaccine against smallpox in previously unvaccinated adults

Conditions: Smallpox

Summary: the purpose of this study is to see how many people respond to a smallpox vaccine when a sore forms where the shot was given. the world was declared free of smallpox in 1980. general routine vaccinations for smallpox were stopped in the u.s. in 1971. in 1976, the recommendation for routine vaccination of healthcare workers was also discontinued. the only people who presently receive this vaccine are people who work with vaccinia virus or monkeypox virus. because the world was considered free of smallpox infections, this vaccine was no longer produced; there is a limited supply available in the united states. because of the limited amount of dryvax vaccine (vaccinia virus) against smallpox, this study will look at the ability to dilute the vaccine making more doses available in the event of a smallpox outbreak. the study seeks to characterize a strategy of vaccination against smallpox with various doses of dryvax, followed by revaccination with the same dose, if required, in volunteers 18-32 years of age with a negative history of smallpox vaccination.


Eligibility criteria:
inclusion criteria: patients may be eligible for this study if they: * are between 18 and 32 years of age. * give written informed consent. * are available for follow-up for 2.5 months. * have an acceptable medical history by screening evaluation and brief clinical assessment. * are hiv-negative. * agree to use acceptable contraception and to not get pregnant during the study. exclusion criteria: patients may not be eligible for this study if they: * have a suppressed immune system. * have participated in an hiv vaccine trial. * have liver disease, diabetes, or kidney problems. * have malignant skin cancer. * have autoimmune disease. * have used medication that suppresses the immune system. * have had psychiatric or medical problems or have job responsibilites that will keep them from participating in the study. * use illegal intravenous drugs. * have received any live vaccines within 60 days of study start. * have used experimental therapies within 30 days before study start. * have been vaccinated with certain experimental vaccines. * have a vaccination scar but have no record of having a vaccine. * have received a smallpox vaccine. * have taken blood products or immunoglobulin in the past 6 months. * have a fever on the day of vaccination. * have certain skin disorders, including eczema, exfoliative skin, lacerations that require stitches or burns larger than 2 x 2 cm. * live with, have sexual contact with, or work with anyone who is pregnant, less than a year old, has eczema, has certain skin disorders, has a disease or takes medication that suppresses the immune system. * have a condition that, in the opinion of the investigator, might interfere with the study. * are allergic to any parts of the vaccine. * are allergic to thimerosal, immunoglobulins, cidofovir, or probenecid. * are pregnant or breast feeding.

Keywords: vaccine prophylaxis
a study of zd1839 effects on cell proliferation in breast cancer

Conditions: Breast Cancer

Summary: this is a phase ii, randomised, double-blind, placebo-controlled study. subjects with histologically-confirmed oestrogen receptor negative (er-), progesterone receptor negative (pgr-) primary breast cancer breast cancer will be randomly assigned in a 2:1 ratio to receive zd1839 250 mg once daily or matching placebo for a total period of 5 weeks. surgical intervention will take place after 4 weeks (on day 29) and treatment will continue for 1 week after surgery.


Eligibility criteria:
inclusion criteria: * histologically-confirmed er- and pgr- primary breast cancer * stage t .5 cm, n0-1, m0 * no previous treatment for breast cancer exclusion criteria: * alt or ast greater than 2.5 times the ulrr * metastatic disease